Open AccessInterference of the CD30–CD30L Pathway Reduces Atherosclerosis Development
Author(s) -
Amanda C. Foks,
Ilze Bot,
Vanessa Frodermann,
Saskia C.A. de Jager,
Mariëtte ter Borg,
Peter J. van Santbrink,
Hideo Yagita∥,
Johan Kuiper,
Gijs H.M. van Puijvelde
Publication year - 2012
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.112.300509
Subject(s) - tumor necrosis factor alpha , cd30 , splenocyte , immune system , t cell , biology , cell growth , immunology , endocrinology , medicine , biochemistry , immunohistochemistry
Costimulatory molecules tightly control immune responses by providing positive signals that promote T-cell activation or by transducing inhibitory signals that limit T-cell responses. CD30 and CD30L are members of the tumor necrosis factor receptor superfamily and are involved in the activation and proliferation of T and B cells, which have been implicated in the initiation and progression of atherosclerosis. In the present study, we thus aimed to determine the role of the CD30-CD30L pathway in the development of atherosclerosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom